Eagle Pharmaceuticals ($EGRX) Investor Settlement
Eagle Pharmaceuticals has agreed to a settlement with $EGRX investors to resolve claims that it misled them about product performance and financial controls related to its cancer drug PEMFEXY.
Outline:
Eagle promoted PEMFEXY as a strong revenue driver and highlighted continued demand for the product. Investors later alleged the company failed to disclose slowing sales caused by excess and expired inventory at a key wholesale customer. When Eagle restated revenue tied to these issues, the stock fell. Investors filed suit, and the parties later reached a tentative settlement.
Timeline:
August 8, 2022: Eagle filed its Q2 report, stating it expected continued pull-through for PEMFEXY.
November 2022–February 2023: The company highlighted PEMFEXY revenue while allegedly failing to disclose inventory issues.
May 2023: Eagle restated revenue figures due to expired inventory tied to a key wholesale customer.
Mid 2023: $EGRX declined as more details about the issue emerged.
December 2023: Investors filed suit.
October 2025: The parties reached a tentative settlement.
Background:
Eagle Pharmaceuticals marketed its chemotherapy drug PEMFEXY as an important contributor to the company’s revenue growth. During earnings calls and public filings, the company emphasized strong demand and ongoing product uptake.
Investors later alleged that a key wholesale customer was experiencing excess inventory and product expiration, which slowed the expected pull-through of PEMFEXY. According to the complaint, Eagle did not disclose these issues while continuing to report strong revenue tied to the product.
In May 2023, Eagle restated revenue figures after identifying problems tied to expired inventory held by a wholesale customer. The company also faced questions about the effectiveness of its financial reporting controls.
Following these disclosures, $EGRX declined as investors reassessed the company’s financial performance and product outlook. Shareholders alleged Eagle’s earlier statements about PEMFEXY demand and revenue lacked a reasonable basis and misled the market.
What Can Investors Expect Now?
Eagle Pharmaceuticals has agreed to a settlement with $EGRX investors to resolve claims tied to disclosures about PEMFEXY sales performance and related financial reporting controls.
If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.
Frequently Asked Questions
all persons and entities who purchased the publicly traded common stock of Eagle between August 9, 2022 and October 1, 2024, both dates inclusive, and who were damaged thereby. Excluded from the Settlement Class are: persons and entities that suffered no compensable losses;
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
The final payout amount depends on your specific trades and the number of investors participating in the settlement.
If 100% of investors file their claims - the average payout will be $1.18 per share. Although typically only 25% of investors file claims, in this case, the average recovery will be $4.72 per share.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.